Lucía Trilla-Fuertes

Has grant

Country flagSpain

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Doctorado Industrial

Open Date: 2016-10-01

Close Date:

Grant: Close

EPIC-XS-420: Seeking of therapeutic targets in high-risk patients of anal squamous cell carcinoma

Open Date:

Close Date:

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Colorectal cancer (CRC) is a molecular and clinically heterogeneous disease. In 2015, the Colorectal Cancer Subtyping Consortium classified CRC into four consensus molecular subtypes (CMS), but these CMS have had little impact on clinical practice. The purpose of this study is to deepen the molecular characterization of CRC. A novel approach, based on probabilistic graphical models (PGM) and sparse k-means–consensus cluster layer analyses, was applied in order to functionally characterize CRC tumors. First, PGM was used to functionally characterize CRC, and then sparse k-means–consensus cluster was used to explore layers of biological information and establish classifications. To this aim, gene expression and clinical data of 805 CRC samples from three databases were analyzed. Three different layers based on biological features were identified: adhesion, immune, and molecular. The adhesion layer divided patients into high and low adhesion groups, with prognostic value. The immune layer divided patients into immune-high and immune-low groups, according to the expression of immune-related genes. The molecular layer established four molecular groups related to stem cells, metabolism, the Wnt signaling pathway, and extracellular functions. Immune-high patients, with higher expression of immune-related genes and genes involved in the viral mimicry response, may benefit from immunotherapy and viral mimicry-related therapies. Additionally, several possible therapeutic targets have been identified in each molecular group. Therefore, this improved CRC classification could be useful in searching for new therapeutic targets and specific therapeutic strategies in CRC disease.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (5)

Alberto Munoz

Research Professor

Spanish National Research Council (CSIC)

SPAIN
View details

Antje Dittmann

ETH Zürich

SWITZERLAND
View details

Francisco Jose Roig Molina

Associate Professor

Universidad San Jorge

SPAIN
View details

David Hardisson

Full Professor (Catedrático)

Universidad Autónoma de Madrid

SPAIN
View details

José M. Sempere

Associate Professor

Universitat Politècnica de València

SPAIN
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.